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2Abstract
Patient derived xenografts (PDXs) are increasingly appreciated models in cancer research, 
particularly for preclinical testing, as they reflect the patient's tumor biology more accurately than 
cancer cell lines. We have established a collection of 20 breast PDXs and characterized their 
biological and clinical features, as well as their genetic stability. While most PDXs originated 
from triple negative breast cancers (70%), our collection comprised five ER+ cases (25%). 
Remarkably, the tumors that produced PDXs derived from a subset of aggressive breast cancers 
with a high proportion of grade 3 tumors and reduced recurrence-free survival. Consistent with 
this, we found significant differences between the transcriptomic signatures of tumors that 
produced a PDX (Take) and those that did not (No Take). The PDXs faithfully recapitulate the 
histological features of their primary tumors, and retain an excellent conservation of molecular 
classification assignment and Copy Number Change (CNC). Furthermore, the CNC profiles of 
different PDXs established from the same tumor overlap significantly. However, a small fraction 
of CNCs in the primary tumor that correspond to oligoclonal events were gradually lost during 
sequential passaging, suggesting that the PDXs’ genetic structure eventually stabilizes around a 
dominant clone present in the tumor of origin. Finally, de novo occurring genetic events covering 
up to 9% of the genome were found in only a minority of the PDXs, showing that PDXs have 
limited genetic instability. These data show that breast cancer PDXs represent a subset of 
aggressive tumors prone to relapse, and that despite of an excellent conservation of original 
features, they remain genetically dynamic elements.
Highlights: 
• A collection of breast cancer PDXs is described.
• PDXs represent a subset of clinically aggressive breast tumors.
• Most PDXs derive from a dominant genetic subclone present in the tumor of origin. 
• PDXs are genetically dynamic and susceptible to slow drift. 
Keywords: breast cancer, patient derived xenografts, genetic stability, adverse prognosis
3Introduction
Considerable progress has been made in understanding the molecular mechanisms underlying 
breast cancer development. A number of new therapeutic strategies are currently being devised 
aiming at targeting specific oncogenic pathways. However, a significant gap still exists between 
the experimental work and the development of effective clinical treatments. To validate the anti-
tumor potential of candidate drugs, preclinical studies based on model systems must be 
performed, and it is paramount that these models accurately reproduce the biological features of  
the cancer in the patients (Hait et al., 2010). 
 Preclinical research traditionally relies on cell lines established from tumor specimens. 
Cancer cell lines have yielded highly valuable and informative data, and remain indispensable 
models for molecular genetics and biochemistry studies (Kao et al., 2009). However, cancer cell 
lines only partially recapitulate the biology of the original tumors, because they propagate as 
adherent monolayers in vitro, in conditions that differ drastically from those in the tumor. 
Furthermore, a number of cell lines used routinely have been established decades ago and 
passed along from one laboratory to another, thus encountering changes in culture conditions 
that may lead to the derivation of subsets with genetic and phenotypic differences (Nugoli et al., 
2003). Finally, patient tumor material is available in small amounts, which limits the number of 
experiments that can be performed with primary cultures. 
 Human tumors propagated in immunocompromised animals, called patient derived 
xenografts (PDXs) or tumor grafts, could be interesting alternatives to cancer cell lines. 
Research on colorectal and breast cancer has shown that grafts from primary tumors faithfully 
reproduce the histology and morphology of the tumor they stemmed from (Fiebig et al., 2004, 
Marangoni et al., 2007). These pioneer studies were the proof of principle that PDXs could be an 
excellent bridge between clinical material and cancer cell lines, and recent research shows that 
established PDXs are permanent sources of tumor material that can be subjected to treatment 
and monitored for response (Landis et al., 2013). Furthermore, breast cancer PDXs faithfully 
reproduce tumor pathology, growth and metastasis of breast cancer (DeRose et al., 2011), and 
also seem to maintain the genetic characteristics of their original tumors (Petrillo et al., 2012; 
Reyal et al., 2012; Zhang et al., 2013). Together these studies demonstrate the power of PDX 
models for cancer research. 
 We describe here a collection of 20 established breast cancer PDXs that resulted from 
engraftment of 130 primary tumors. To investigate what differentiates tumors that produce PDXs 
from those that do not, we have carefully analyzed the determinants of graft take in breast 
cancer, and characterized the primary tumors and their resulting PDXs by array-CGH and 
transcriptome analysis. We show that tumor grafts from breast cancer display remarkable 
conservation of the morphological and genetic features of the tumor they stem from. CNC 
4profiles remained stable over several passages, but a small fraction of CNCs in the primary 
tumor that corresponded to oligoclonal events were gradually lost during sequential passaging. 
As expected, grade 3 and ER- breast tumors were positively selected in the grafting process 
(Landis et al., 2013; Petrillo et al., 2012; Zhang et al., 2013). Finally, we show that breast tumors 
that give rise to stabilized PDXs derive from a subset of aggressive cancer prone to relapse and 
have a transcriptomic signature clearly distinct from tumors that fail to produce PDXs. 
51. Materials and Methods
1.1 Patients and tumor material 
 A total of 130 fresh breast cancer samples were collected from the pathology department upon 
macroscopic dissections, transferred to the animal facility and implanted within a maximum of 60 
minutes after surgical removal. Full description of all the tumors grafted is provided in 
Supplementary Table 1. This study was reviewed and approved by the Montpellier Cancer 
Center - Val d’Aurelle Institutional Review Board and informed consent was obtained from all 
patients. Samples were systematically anonymized. Mean follow-up time was of 34 months.
1.2 Grafting, passaging and preservation of PDXs 
This project was first reviewed and approved by an internal animal ethics committee, and then 
by the University of Montpellier animal ethics committee. There was always a minimum of three 
mice per experimental group. We implanted a single fragment of fresh or frozen tumor (~8 mm3) 
into the inter-scapular fat pads of 3 to 4-week-old female Swiss-nude mice. For ER+ tumors, 
mice were supplemented with estrogen by weekly application on the skin of 10µl of a 15mg/ml 
estrogen (Sigma-Aldricht, St Louis, MI, USA) solution in ethanol. Tumor growth was measured 
weekly using calipers. Tumors were passaged onto a further cohort of mice once grafts reached 
a maximum of 2,000 mm3. At each passage, fragments were (1) frozen at -180°C in L15 culture 
(Sigma-Aldricht) medium, with 40% FCS serum, 10% DMSO, for eventual retransplantation, (2) 
frozen dry at -80°C for DNA, RNA or protein extraction, (3) fixed into 4% buffered formaldehyde 
and embedded in paraffin. 
1.3 Histological analysis 
Histology was assessed on hematoxylin-eosin stained sections. Immunochemistry was 
performed on standard sections, deparaffinized, rehydrated and treated for epitope retrieval in 
boiling EDTA (pH 9). Neutralization of endogenous peroxidase was done with H2O2. Sections 
were incubated for 20 minutes at room temperature with anti-ERa (clone 6F11, 1:100, 
LeicaBiosystems, St Germain en Laye, France), anti-PR (clone PgR636, 1:400, Dako, Glostrup, 
Denmark) mouse monoclonal antibodies. Antibody binding was amplified using the EnVision™ 
FLEX detection system (Dako).  Endogeneous biotin and avidin were saturated with a blocking 
kit (Vector Laboratories-CliniSciences, Nanterre, France). Sections were then incubated with 
primary antibodies or mouse isotype control (Mouse IgG1κ, Sigma-Aldrich) overnight at 4°C. 
Sections were then washed 3X in 0.1% Tween20-PBS solution at 25°C for 3 hours and 
incubated 10 minutes with the secondary antibody. Amplification of the signal was done using 
6the ABC kit (Vector Laboratories-CliniSciences). Sections were washed as above. Binding was 
visualized by incubating with DAB (3,3-diaminobenzidine) substrate. The sections were then 
counterstained with haematoxylin, dehydrated and permanently mounted. Slides were scanned 
with a digital slide scanner NanoZoomer (Hamamatsu). Pictures were visualized and exported 
using NDP.view 1 software. Slides were read by a pathologist (F.B.). The presence of invasive 
carcinoma was assessed and histology of the tumors and corresponding PDX was compared. 
Immunohistochemistry results were evaluated according to standard practice.
1.4 DNA and RNA extraction
DNA and RNA were isolated from frozen tissues using the QIAmp DNA Mini kit and Rneasy Mini 
Kit (Qiagen S.A. France, Courtaboeuf, France). Each DNA sample was quantified by 
nanospectrophotometry (NanoView, GE Healthcare, Orsay, France) and qualified by 0.8% 
agarose electrophoresis. Qualification of mRNA was performed using a Bioanalyser (Agilent, 
Santa Clara, CA, USA). 
1.5 Array-CGH
The genomic profiles were obtained by array comparative genomic hybridization (array-CGH) 
using HG18 CGH 385K Whole Genome v2.0 array (Roche NimbleGen, Madison, WI, USA). 
DNA from a pool of 20 normal females was used as reference. For hybridization, 1μg of genomic 
DNA and reference DNA were labeled using NimbleGen Dual-Color DNA Labeling Kit (Roche 
Diagnostics, Meylan, France). Labeling products were precipitated with isopropanol and 
resuspended in water. Test (Cy3) and reference (Cy5) samples were combined in 40μl of 
NimbleGen Hybridization buffer. Hybridization was performed in a NimbleGen Hybridization 
system 4 for 48 hours at 42°C with agitation mode B and washed using NimbleGen Wash Buffer 
kit according to manufacturer’s instructions. Arrays were scanned at 5μm resolution using the 
GenePix4000B scanner (Axon Instruments, Molecular Devices Corp., Sunnyvale, CA). Data 
were extracted from scanned images using NimbleScan 2.5 extraction software (Roche 
NimbleGen, Madison, WI, USA), which allows automated grid alignment, extraction, 
normalization, and export of data files. Normalized files were used as input for the Nexus 6.1 
Software (Biodiscovery, El Segundo, CA, USA). Analysis settings for data segmentation and 
calling were the following: significant threshold for FASTST2 Segmentation algorithm: 1.0E-7, 
Max Continuous Probe Spacing: 1000, Min number of probes per segment: 10, high level gain: 
0.485, gain: 0.17, loss:-0.2, homozygous copy loss:-0.485. Hierarchical clustering was done 
using Nexus 6.1 using average linkage setting.
71.6 Expression profiling and molecular classification
Expression profiling was performed on Affymetrix Human Genome GeneChip U133Plus2 and 
Biotinylated cRNA were prepared according to the Affymetrix IVT Express protocol from 100 or 
200ng total RNA and hybridization was done as follows. CRNA were fragmented, 12µg 
hybridized for 16 hr at 45°C, washed and stained in the Affymetrix Fluidics Station 450 with 
Hybridization Wash & Stain kit. GeneChips were scanned using the Affymetrix GeneChip 
Scanner 3000 7G. Raw feature data were normalized using Robust Multi-array Average (RMA) 
method (R package affy). All subsequent analyses were performed on normalized datasets. For 
the CIT/Guedj classification we applied a classical distance-to-centroid approach, implemented 
in the citbcmst R package available at http://cran.rproject.org/web/packages/citbcmst/
index.html). For further details see (Guedj et al., 2011). For the Hu, PAM50 and Sorlie 
classifications we implemented the script published by Alan Mackay available at http://
rock.icr.ac.uk/collaborations/Mackay/centroid.correlations.Eset/ExpressionSet Nearest Centroid 
Correlations.pdf). For the BasalA/B classification we used the gene centroid list as in (Neve et 
al., 2006). Pearson metrics was employed for all classifications except for Sorlie (Spearman 
metric). For the VEGF and IL8 signatures the function sig.score from the R program package 
Genefu was used to compute a signature score after MAS5 normalization of the data (R 
package affy). Probes list are included in the IL8 (Hu et al., 2009), VEGF (Waugh and Wilson, 
2008) and proliferation (Rody et al., 2011) lists are shown in Supplementary Table 2.
1.7 Survival analyses
On grafted tumors we performed Univariate Kaplan-Meier analysis with a log-rank (cox-Mantel-
Haenzel) test using the GenePattern package. The CIT cohort dataset was dowloaded from 
Arrayexpress (E-MTAB-365) and the 428 samples stratified with survival follow-up data as ER+ 
or basal-like subtype. Univariate Kaplan-Meier was performed with a log-rank (cox-Mantel-
Haenzel) test using GenePattern package with the VEGF signature. 
1.8 Exome sequencing 
High-throughput exome sequencing was performed by Integragen (Evry, France) using the 
Human All Exon v4 -70 Mb kit (Agilent) followed by 75 base end-sequencing on an Illumina 
HiSEQ 2000 on 6 samples at a mean 60X depth from three primary/PDXs pairs (Gnirke et al., 
2009). Bioinformatic analysis used the pipeline provided by Illumina (CASAVA1.8) on the build37 
of the human genome and with ELANDv2e alignment algorithm. Annotation includes gene 
(Refseq), polymorphism (dbsnp132, 1000 genomes) and frequency of mutation in Integragen 
database (IGdb) of 150 expected to be normal Exome sequenced at Integragen facilities. For 
each mutation, localization (exon, intron) as well as effect (missense, no-sense, synonymous ) 
8was annotated. Variant detection was done by pair (Primary/PDX) with CASAVA1.8 (Theta 
=0.01). This is the standard pipeline for output delivered by our contractor (Integragen SARL, 
Evry). Due to the absence of Normal blood DNA sequencing from the patient the filtering was 
done according to a stringent strategy in three steps as described below.  (1) Mutations present 
in the 1000 genomes database or in IGdb were excluded from analysis as they represent 
polymorphisms or sequencing errors. (2) Only missense or nonsense mutations were 
considered. (3) Only the 518 genes previously found to be mutated twice in (Banerji et al., 2012) 
or in the Significantly mutated genes list of (Koboldt et al., 2012) were included. This filtering 
process in three steps resulted in the approval of 35 mutations for B3977 samples and 28 
mutations for B3029 and 5 for the B3921 case (SupTable 3). Due to this low number of 
mutations in B3921, we considered this sample as unsuitable to determine a general trend in the 
comparison between primary and PDX. Frequency of the mutated allele was calculated in the 
primary and the PDX on the basis of respective read numbers. 
1.9 Statistical Analysis
Anova or t-test were performed when appropriate using the Rcmdr R package. Multivariate 
logistic regression analysis was performed to identify independent predictors of the “PDX take”.
92. Results
2.1 Establishment of the breast tumor PDX collection
With the aim to establish stabilized breast cancer PDXs, we grafted a total of 130 fresh breast 
tumor specimens into the inter-scapular fat pad of Swiss-Nude mice within an hour of surgical 
resection. We chose to graft into the inter-scapular fat pad rather than the mammary gland 
because of quicker and easier handling, as our strategy was to graft rapidly a large number of 
tumors within a limited time span. We rarely observed macroscopic metastases to the lung and 
never to the liver. All grafted breast tumors were primary tumors, except one tumor that was a 
local recurrence from a primary breast cancer treated three years earlier in our institution. We 
observed take (tumor regrowth at first graft) in 39 (30%) cases and stabilization (after at least 
three serial passages) of 20 (15%) PDX lines. Thus, 19 grafts that initially took were not 
sustained beyond one or two passages. The majority of these grafts (15/19) were ER+ tumors 
with a slow growth rate. Indeed, while established PDXs required on average 130 to 150 days of  
growth between each passage (and 63 days for a group of fast growers; Figure 1), non-
established grafts took about 15 months to become palpable. These slow-growing grafts were 
therefore at increased risk of being lost because of premature death of the recipient animal. We 
found a significant correlation between PDX take and/or establishment, and steroid receptor 
levels and SBR grade (Table 1). Indeed, a majority of PDXs were of the ER/PR/HER2 triple 
negative (TN) phenotype (14/20) and predominantly mutated at the TP53 gene (65%), while only 
five PDXs were ER+ and three were HER2+ (two ER+/HER2+ and one ER-/HER2+) (Figure 2, 
Supplementary Figure 1B and 1C). 
2.2 PDXs reproduce the phenotype of the tumors they originate from
We next investigated whether the PDXs retained the phenotypic features of the tumors of origin. 
We found that indeed they showed remarkable conservation of histological and morphological 
features (Supplementary Figure 1A). Furthermore, immunohistochemical staining in PDXs 
originating from ER+ tumors showed that ER and PR expression was stably conserved during 
passages (Supplementary Figure 1B). We also detected matching HER2 overexpression 
patterns in HER2+ primary tumors and their corresponding PDXs (Supplementary Figure 1C). 
To further assess the phenotypic stability of the PDXs in reference to the primaries, we 
examined their respective assignments into molecular subtypes. We established expression 
profiles for the primary tumors and PDXs on Affymetrix U133 Plus 2 GeneChips, and then 
classified them according to the CIT/Guedj classification (Guedj et al., 2011). Next, we compared 
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these results with four other nearest centroid classifiers (Figure 2). Of the 20 tumors that gave 
rise to grafts, 13 were assigned to the Bas-L (in coherence with their TN phenotype), two to the 
ER- mApo (one had been diagnosed HER2 3+, while the second was determined HER2 1+) and 
five to ER+ Lum-B or Lum-C molecular subgroups of the CIT/Guedj classification (Guedj et al., 
2011). Subgroup assignments using these classifiers were globally concordant, thus confirming 
the conservation of the expression characteristics between primaries and PDXs (Figure 2). 
Together these results show that breast cancer PDXs faithfully reproduce the phenotype of the 
tumor of origin.
2.3 PDXs preserve copy number change profiles of the original tumor
To assess the genomic stability of the PDXs, we established copy number change (CNC) 
profiles of primary tumors and their PDXs by array-CGH on high density oligo-chips. Similar 
patterns of genomic aberrations in PDXs and the primary tumors they originated from suggest 
that CNC profiles evolve in parallel in primary tumors and their grafts (Supplementary Figure 
2A). However, in a number of cases the CNC profile of the primary tumor was less accentuated 
than the corresponding PDX profile, which resulted in a higher number of aberration call in the 
grafts (Supplementary Figure 2A). This effect could be explained by variable contingents of 
contaminating normal stromal cells in the primary tumors, resulting in the dilution and 
subsequent attenuation of the CNC signal. In the PDXs, contamination by normal tissue should 
not occur because stromal cells do not interfere with the tumor DNA signal, as they have murine 
origin and there is limited homology on our arrays. We estimated the fraction of normal cells 
present in each primary tumor and then inferred the level of dilution of tumor DNA by normal 
DNA in the CNC profiles of primary tumors. CNC profiles of primary tumors and PDXs were then 
normalized taking this dilution factor into account. Indeed, normalization led to a significant 
decrease in the divergence between CNC profiles from primary tumors and their corresponding 
PDXs (Supplementary Figure 2B, 2C). Furthermore, clustering analysis performed on corrected 
profiles revealed that PDXs and their cognate primaries were systematically co-clustered, thus 
showing a high level of correlation (Figure 3). 
 Next, we analyzed the genetic stability of the PDXs during passages. Visual inspection 
revealed that CNC profiles of different grafts obtained from the same tumor were almost 
interchangeable (Figure 4C). Consistent with this, when compared to the primary tumor, the 
concordance ratio of CNC profiles of PDXs from passages 0, 1 or 2 suggests that changes 
occurred mainly during the initial graft (Figure 4B). These data indicate that propagation of 
breast tumors as xenografts on immunocompromised mice preserves preexisting genomic 
features, and that these genomic features change little during passages.
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2.4 PDXs uncover limited levels of oligoclonality in breast tumors 
Despite the genomic conservation of the PDXs and their tumors of origin, a detailed analysis of 
the CGH-profiles revealed that a fraction of the CNCs showed divergence at specific loci 
(examples are shown in Supplementary Figure 3A and Supplementary Figure 3B). We were 
interested in CNCs present in the tumors of origin but absent in the PDXs, which were clear 
signs of oligoclonality in the primary tumor. According to the tumor analyzed, these events 
represented up to 6% of the human genome (Figure 5A) and reached at least 2% in about half of 
the tumors. These findings suggest that a limited but sizeable level of oligoclonality is present in 
our breast cancer set. We next determined the precise fraction of de novo occurring anomalies 
in the PDXs when compared to the original tumors, as these de novo events are representative 
of ongoing genetic instability. We compared the CGH profiles of the PDXs and their cognate 
primary tumors after correction for normal stromal cells contamination (Supplementary Figure 2). 
Similarly to oligoclonal anomalies, de novo events fluctuated from one PDX line to another, 
representing 0.3 to 9% of the human genome, with a quarter of the lines encompassing at least 
4% of the genome (Figure 5B). Importantly, we observed no correlation between elevated 
oligoclonality and high occurrence of de novo CNCs. Results obtained from CGH profiles were 
confirmed by exome sequencing performed on a subset of three primary tumor/PDX pairs that 
we selected because of their CNC profile differences. However, since we could not obtain 
normal tissue from the patients to use as reference, our determination of somatic mutations 
could not be definitive. To circumvent this pitfall, we restricted our analysis to a subset of genes 
with mutations and indels described in previous high-throughput sequencing studies on breast 
cancer (Banerji et al., 2012; Koboldt et al., 2012). We were able to identify in each of the three 
breast tumors analyzed 5, 28 and 32 genes with deleterious mutations, respectively 
(Supplementary Table 3), and to compare the mutation frequency in the primary tumor vs the 
PDX (Supplementary Figure 4). In the primary tumor/PDX pairs with sufficient numbers to 
perform a statistical analysis, we found that mutation frequencies in the PDXs and in their 
original tumors were highly correlated (R2 coefficient 0.65 and 0.80). In particular, we observed a 
general trend toward an enrichment of mutation frequencies in the PDXs, probably as a 
consequence of the elimination of normal stromal cells. While a minority of the mutations 
(possibly representing founder or essential events such as TP53) was selected to homogeneity 
in the PDXs, a large fraction of the mutations remained at an intermediary frequency rate (0.25 
to 0.7) indicating that they were not subjected to a drastic selection process. Mutations restricted 
to the primary tumor (and lost in the PDX) represented 5.7% and 17% for B3977 and B3029 
respectively. These results confirm our CNC data showing sizable levels of oligoclonality in 
these tumors. A limited set of de novo events (seven events in two cases) were also found. 
Together these data show that there are differences in clonality in our breast cancer PDX 
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collection, but that there is a general tendency for the gradual emergence of a dominant clone in 
the PDXs after three passages. Limited genetic drift could also be observed.
2.5 Breast tumors that take correspond to a subset of aggressive breast cancer.
The prevalence of grade 3 and TP53-mutated tumors in our PDX collection suggested that 
stable grafts could represent a subset of aggressive breast cancers. A multivariate regression 
logistics analysis showing that PDX take was significantly associated to Grade 3, ER- and 
metastatic disease further supported this model (Supplementary Table 4). To investigate the link 
between PDX take and aggressive breast cancer, we compared recurrence-free survival (RFS) 
in the breast cancer patients. Indeed, we found that patients whose primary tumor gave rise to a 
PDX had a lower RFS than patients whose tumor did not take (Supplementary Figure 5A). RFS 
may reflect known differences in outcome between TN basal cancers (predominant in the Take 
group) and ER+ luminal cancers (overrepresented in the No Take group). However, when we 
stratified the patients in TN and ER+ tumors, we still found a significant difference between RFS 
in the Take and the No Take groups in ER+ tumors, and an observable trend in TN breast 
cancers (Supplementary Figure 5B, 5C). 
 The contrast between outcome in patients from Take and No Take groups raised the 
possibility that tumors that produce PDXs have distinct gene expression signatures from tumors 
that do not take. Our first attempt to identify a set of genes differentially expressed in the breast 
primary tumors using a supervised approach did not succeed because of limited sample size 
and insufficient statistical power. We therefore selected 16 expression signatures with reported 
prognostic significance in breast cancer to test for significant transcriptomic differences in the 
primary tumors used in our set. Five of these expression signatures showed a significant 
increase in the Take group, namely GGI-grade  (Sotiriou et al., 2006), proliferation (Rody et al., 
2011), wound healing (Chang et al., 2004), VEGF (Hu et al., 2009) and IL8 (Waugh and Wilson, 
2008)(Figure 6). To avoid a confounding effect due to compositional differences, we classified 
the tumors according to molecular subtypes (namely Bas-L and Lum-B/Lum-C for the two 
subtypes with a sufficiently large sample size) and repeated the signature analysis. Remarkably, 
GGI-grade was significantly increased in the Take vs the No Take groups in both Bas-L and Lum 
tumors, while three signatures showed a restricted pattern. The wound healing signature was 
significantly increased in the Take group in Lum-B/Lum-C tumors, whereas VEGF and IL8 
signatures were restricted to the Take group in Bas-L tumors. Interestingly, the proliferation 
signature showed differential expression in Lum tumors but did not reach significance, likely due 
to small sample size. Taken together, these results show that tumors that give rise to PDXs 
correspond to a distinct subgroup of aggressive breast cancers irrespective of the molecular 
subtype they belong to. 
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3. Discussion
3.1 Grafting efficiency 
In comparison to other cancers, such as colorectal cancer, breast cancer PDXs are 
characterized by a relatively low take rate upon grafting on immunocompromised mice. In 
particular, several studies have shown that high grade and ER- negative tumors are 
overrepresented in breast PDXs (DeRose et al., 2011; Landis et al., 2013; Marangoni et al., 
2007; Zhang et al., 2013). Our work is consistent with these findings, given that from the 20 
stabilized PDXs we established, 14 stemmed from TN breast cancers and 18 were grade 3. 
Furthermore, the number of takes at first graft (39 take out of 130 grafts) was almost double the 
number of stabilized PDXs (at least three passages). Grafts that we could not stabilize were 
predominantly slow-growing ER+ tumors. It therefore appears that despite estradiol 
supplementation and grafting on female mice, ER+ breast tumors (predominantly of grade 2 in 
our series) are negatively selected in this system. 
! Research on melanoma shows that some xenografts may require severely 
immunosuppressed animals, such as NOD-SCID gamma-delta mice, and it has therefore been 
proposed that the level of immunosuppression of recipient mice is a determinant factor for graft 
stabilization (Quintana et al., 2008). However, our attempt to graft on severely 
immunocompromised mice did not lead to a clear breakthrough, consistent with what others 
reported for breast cancer grafts (DeRose et al., 2011; Landis et al., 2013). It has also been 
suggested that the graft site could make a difference in graft take rates. For instance, breast 
cancer orthotopic grafting in cleared mammary fat pads has been preferred by several groups, 
but did not lead to a clear increase of ER+ tumor take rate (DeRose et al., 2011; Zhang et al., 
2013). Another alternative could be to graft into the renal capsule (Cutz et al., 2006), however, 
this is a complex procedure and it is therefore not very commonly used. Hence, primary breast 
tumor grafting is still open for improvement and co-grafting of mesenchymal feeder cells or 
engineered mice expressing cocktails of cytokines could represent interesting leads. 
3.2 PDXs represent a subset of aggressive and recurrence-prone breast tumors
In our collection the permanently stabilized PDXs corresponded to a subset of aggressive breast 
cancers associated to a lower RFS. This correlation between graft stabilization and cancer 
aggressiveness is in line with reports showing that metastatic lesions, such as pleural effusions, 
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have a high take rate (Landis et al., 2013). We found that the potential to take and produce 
xenografts is inherent to the primary tumors, as demonstrated by the clear differences at the 
RNA expression level between tumors that took and those that did not. Overall, tumors 
producing stable PDXs showed increased expression of several gene signatures associated with 
adverse prognosis, namely GGI, wound healing, proliferation, IL8 and VEGF (Chang et al., 
2004; Hu et al., 2009; Rody et al., 2011; Sotiriou et al., 2006; Waugh and Wilson, 2008). The 
core of the first three signatures is built around genes governing cell cycle progression, DNA 
synthesis and repair genes, which suggests there is increased proliferation in the tumors of the 
Take group. Elevated expression of IL8 and VEGF is characteristic of aggressive breast tumors. 
In particular, elevated VEGF expression is known as a marker of adverse prognosis in breast 
cancer and is associated with hypoxia and increased vasculature (Dhakal et al., 2012; 
Gasparini, 2000) (Supplementary Figure 6). Furthermore, increased IL8 signaling in breast 
cancer has been shown to favor cancer stem cell maintenance and propagation (Ginestier et al., 
2010, Fernando et al., 2011), by way of cross-connections with PI3K/AKT and SRC (Hartman et 
al., 2013; Singh et al., 2012). It is reasonable to assume that elevated production of IL8 and/or 
VEGF by tumor cells (Hu et al., 2009; Rody et al., 2011; Waugh and Wilson, 2008) could be 
critical for the grafting process and thus contribute to the higher take rate of basal-like breast 
tumors, for instance, by favoring cancer stem cell renewal and the angiogenic shift necessary to 
the long-term establishment of tumors of large size (Waugh and Wilson, 2008). 
3.3 PDXs reproduce the phenotypic and genetic characteristics of the grafted tumor 
fragment
An excellent conservation of the histological features of the tumor of origin in breast cancer 
PDXs was first shown by Marangoni and colleagues (Marangoni et al., 2007), and then 
repeatedly observed by others (DeRose et al., 2011; Landis et al., 2013). Our results are in 
agreement with these observations, thus confirming that PDXs perfectly recapitulate the 
morphological characteristics of primary tumors. Because sporadic loss of ER expression in 
PDXs established from ER+ breast tumors has been reported (Bergamaschi et al., 2009), we 
carefully checked ER expression in our PDXs. However, we could not observe any reversion of 
ER expression in our ER+ PDXs (Supplementary Figure 1B). Importantly, these findings were 
corroborated by transcriptome analysis in the primary tumors and corresponding PDXs, which 
show very similar expression profiles and molecular classification assignments, in concordance 
with recent research (Petrillo et al., 2012). 
 Besides transcriptomic stability, the PDXs show remarkable stability at the genomic 
level, as clearly demonstrated by the excellent conservation of the CNC profiles of the tumors of 
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origin. These results differ slightly from that of Reyal and coworkers, however, who observed a 
global increase in the number of CNCs in the PDXs (Reyal et al., 2012). Our analysis suggests 
that this discrepancy can be attributed to the presence of large contingents of contaminating 
stromal cells in the primary tumors, which dilutes out the tumors’ DNA signal. Interestingly, we 
found that the CNC profiles in different PDXs established in parallel from the same tumor are 
nearly identical. These findings are very reassuring concerning the genetic stability of breast 
PDXs and their reliability as cancer models. We also found that oligoclonal CNC differences 
represent 0.2 to 6% of the genome, depending on the primary tumor, which is significantly less 
than what others reported for some breast tumors (Nik-Zainal et al., 2012). It is possible that our 
assessment of oligoclonality levels based on CNC profile differences is an underestimation, 
when compared to the levels detected by whole genome sequencing. Nevertheless, our data are 
consistent with findings by Nik-Zainal and colleagues (2012) showing that oligoclonality varies 
appreciably from one breast tumor to another, and that the genetic structure of each tumor 
stabilizes around a dominant clone (Nik-Zainal et al., 2012). The analysis of different PDXs 
established from the same tumor revealed that there is gradual loss of the minor clones over 
sequential passages. This result is however not surprising, as grafting onto 
immunocompromised mice represents a change of environment and selective pressure. In 
addition, gradual loss of minor clones could also result from the outgrowth of de novo occurring 
mutations. 
 In summary, our results show that PDXs are a faithful representation of the tumor of 
origin, but sequential passages are associated with gradual selection of a dominant genetic 
clone and some models can show limited genetic drift. These data suggest that PDXs are 
dynamic biologic elements that should therefore be regularly checked for genetic and phenotypic 
stability. 
3.4 PDXs as cancer models 
Grafts established from clinical tumor material are increasingly appreciated models for preclinical 
testing because they are closer representations of the disease than cancer cell lines. PDXs are 
particularly well suited to test targeted therapy, as they can be comprehensively characterized at 
the molecular level. PDXs also allow detection of the oncogenic cascades that fuel the tumor. 
One could therefore expect that grafts will be increasingly used for the definition of therapeutic 
combinations, and they should play an important role in the current therapeutic evolution toward 
personalized medicine. Furthermore, PDXs could be key for unraveling the causes and the 
mechanisms underlying treatment failure, and for testing alternative therapies to overcome 
tumor resistance. Indeed, resistant and sensitive sublines can be derived from tumors with a 
clinically documented response to therapy, and sublines with variable levels of treatment 
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sensitivity can be further established in vivo (Landis et al., 2013). Hence, a precise assessment 
of the tumor’s level of oligoclonality and/or genetic plasticity could be of great value. Combined 
with short term ex vivo culture, it is foreseeable that PDXs will give rise to families of genetically 
modified models expressing shRNA, specific target genes or reporter genes, which will open the 
way to functional assays similar to those currently performed in cancer cell lines. For instance, 
fluorescent or luminescent models will be of special interest to monitor metastatic dissemination 
using in vivo imaging and to test compounds for the reduction of the tumor burden.
 In summary, we have established a valuable collection of breast cancer PDXs that 
faithfully reproduce the tumors of origin. We have shown that breast PDXs retain transcriptomic 
and genomic stability over sequential passages, with gradual selection of a dominant genetic 
clone. Our results show that breast tumors producing stabilized PDXs derive from a subset of 
aggressive cancers associated with a poor clinical outcome, and that despite of an excellent 
conservation of original features, they remain genetically dynamic elements. We conclude that 
our PDX collection could be an important model for breast cancer research and preclinical 
testing. 
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1.Legends to the Figures:
Figure 1: growth kinetics of established breast PDXs. The average duration of the 3 first 
passage was calculated for each PDX and used as an estimate of their growth rate. Time is 
presented in days. Each bar represents a PDX. Color of the bar indicates the molecular subtype 
to which the PDX was assigned. As shown in Figure 2 red=Bas-L, light blue=Lum-B, pink=Lum-
C, orange=m-Apo. 
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Figure 2: Molecular classification of PDX and tumors of origin are highly concordant. Identical 
assignment were found in 87 % of the cases with at least 3/5 identical classifications for each 
PDX. Divergences were restricted to the luminal subtypes. Transcriptomes of PDX and 
corresponding tumor of origin were classified using the Guedj, Hu, PAM 50, Sorlie and Neve 
breast cancer classifiers and assignments were indicated by a color code. Red: Basal or Bas-L, 
Orange: M-Apo (ER-/HER2+), Pink: Lum-C (ER+/PR-), light blue: Lum-B (ER+/PR+/HER2-), 
dark blue: Luminal A. ER, PR status determined by IHC is presented in red for ER-, in green for 
ER+. HER2 status was noted negative in green when scored <2+, positive in red score = 3+. 
TP53 mutation status determined by DNA sequencing, mutated in red, wt in green.
Figure 3: Breast tumors of origin and corresponding PDXs show elevated similarity at the 
genomic level. CNC profiles of all PDXs (* indicates corrected profiles) and breast tumors of 
origin were determined by array-CGH and convergence tested by clustering analysis. Breast 
tumors and their cognate PDXs were systematically clustered together (pairs, triplet or quadriplet 
according to profile availability).
Figure 4: CNC profiles of different grafts from the same primary tumor remain remarkably 
stable .A: Graft tree indicating the position of the analyzed PDXs which have been highlighted by 
a color code. B: Histograms showing the fraction of overlapping events in the tumor of origin and 
the corresponding PDX which are identified by color codes indicated in the graft tree. C:  whole 
genome CNC profiles, gains are shown in blue, losses in red, chromosomes by alternating light 
blue and white bars. Samples are identified as shown in the tree
Figure 5: quantification of CNC specifically found in each primary tumors (A) or specific of each 
PDX (B). Events specific to the tumors give an insight on tumor heteroclonality, whereas those 
found only in the PDX represent events acquired de novo during propagation in the mice. A: 
Each bar represents the percentage of the genome interrogated by the array involved in primary 
tumor specific CNC. B: the fraction of the genome corresponding to CNC occurring de novo in 
the PDX. CGH profiles of the PDXs and cognate primary tumors were analyzed after correction 
for the contamination by normal stromal cells. 
Figure 6: Expression differences between primary tumors that give rise to PDX (Take) and those 
that did not (No Take). Number of cases in each category are indicated in brackets. We analyzed 
5 expression signatures with known prognostic showed significant expression differences.  The 
tumor set was stratified according to molecular subtypes to verify whether these differences 
24
were not due to differences in composition of the Take and the No Take groups. GGI identifies 
the molecular grade signature. 
2.Legend to Table 1
Table 1: Clinical and pathological characteristics that differentiate breast tumors that give rise to 
a PDX from those which fail to do so. Distribution of characteristics showing significant 
differences are presented for tumors that gave rise to primary take (passage 1) and tumors that 
reached passage 3 (a stage at which the PDXs were stabilized). Tumor Grade was determined 
according to the EE-SBR guide lines. Estrogen and progesterone receptor status was assessed 
by immunohistochemistry and scored as defined in the Materials and Methods section.
